<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023309</url>
  </required_header>
  <id_info>
    <org_study_id>010246</org_study_id>
    <secondary_id>01-DK-0246</secondary_id>
    <nct_id>NCT00023309</nct_id>
  </id_info>
  <brief_title>Lamivudine and Adefovir to Treat Chronic Hepatitis B</brief_title>
  <official_title>Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of lamivudine plus adefovir versus
      adefovir alone to treat chronic hepatitis B infection. The Food and Drug Administration has
      approved lamivudine for the treatment of hepatitis B. However, the drug is not effective in
      all patients, and many of those in whom it initially works develop resistance after 1 to 3
      years. Adefovir is an experimental drug that inhibits replication of the hepatitis B virus
      (HBV). Adefovir used alone may be adequate to provide sustained suppression of the virus and
      improvement in liver disease. However combining two anti-viral agents may be superior to
      using one alone, similar to the strategy employed for the treatment of AIDS. This study will
      test whether the combination of lamivudine and adefovir is better than adefovir alone for the
      treatment of chronic hepatitis B.

      Patients 18 years of age and older, who have been infected with HBV for at least 6 months,
      may be eligible for this study. Candidates may not have received lamivudine treatment in the
      past 6 months or prior treatment with adefovir and must not be taking other anti-viral
      treatments for their hepatitis. They will have a blood test to confirm HBV infection.

      Participants will be admitted to the NIH Clinical Center for 2 to 3 days for a medical
      evaluation. One to 2 weeks after the evaluation, patients will be randomized to begin taking
      lamivudine and adefovir, or adefovir alone. Therapy will continue for at least 12 months.
      Follow-up clinic visits will be scheduled weekly for the first month, then every 4 to 8 weeks
      for the rest of the treatment period. Patients will be evaluated at the end of 1 year.
      Patients who have not improved with treatment will stop taking the treatment and will be
      evaluated in the clinic once every 4 weeks for another 6 months. Patients who show an
      improvement in their liver injury may continue taking lamivudine and adefovir or adefovir
      alone for 4 more years, as long as they continue to improve with the medication. Progress
      will be evaluated. If the test results show no continued improvement or are negative for
      hepatitis B antigens, therapy will be stopped.

      Patients who continue treatment for 5 years will be readmitted at year 4 for another medical
      evaluation to assess the effects of treatment at that time. After the 5 years all patients
      will stop therapy at and be followed with regular clinic visits for at least 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims: To assess the safety, antiviral activity and clinical benefit of the combination of
      lamivudine and adefovir dipivoxil vs adefovir alone in up to 80 patients with chronic
      hepatitis B for up to five years.

      Background: Adefovir dipivoxil and lamivudine are oral antiviral agents that have been shown
      to have potent activity against HBV in vitro and in vivo. Both drugs have been used
      extensively in patients with HIV infection and more recently in controlled trials as
      monotherapy in patients with chronic hepatitis B. Lamivudine is currently approved as therapy
      of hepatitis B and has been evaluated extensively both as a one-year course of treatment as
      well as long-term continuous therapy. While lamivudine monotherapy induces a transient
      improvement in viral levels and liver histology, viral resistance develops in a large
      proportion of patients with re-appearance of HBV DNA in serum in high levels associated with
      mutations in the Tyrosine-methionine-aspartate-aspartate (YMDD) motif of the HBV polymerase
      gene and worsening of the hepatitis. Adefovir monotherapy, in contrast, has not been shown to
      be associated with development of viral resistance even when given for up to two years. When
      given as monotherapy for 1 year, adefovir leads to improvement in histology of hepatitis B in
      approximately 50% of patients. At present, the long-term efficacy of adefovir has not been
      shown.

      Protocol: Up to 80 patients with chronic hepatitis B who have raised serum ALT (alanine
      aminotransferase) levels, HBV DNA in serum (above 1 million copies per ml by quantitative
      PCR) and active liver disease on liver biopsy will be enrolled and started on the combination
      of lamivudine (100 mg daily) and adefovir dipivoxil (10 mg daily) or adefovir alone (10 mg
      daily). Patients will be stratified into one of four groups of 20 patients for randomization:
      (A) Lamivudine naive and HBeAg positive, (B) Lamivudine naive and HBeAg negative (C) previous
      lamivudine therapy and HBeAg positive and (D) previous lamivudine therapy and HBeAg negative.
      Patients will be monitored carefully during therapy for adverse events, clinical symptoms and
      signs of liver disease, biochemical, and hematological parameters, and HBV serology at 2 to 4
      week intervals. The primary endpoint of therapy will be a maintained combined response (a
      combination of virological, biochemical, and histological response) with major timing of
      end-points being at 1 and 4 years. Secondary endpoints will include loss of HBeAg, the
      individual types of maintained responses (virological, biochemical and histological), the
      development of lamivudine resistance, and improvement in symptom scores and quality of life
      assessments at 1 and 4 years.

      Conclusions: This study will assess the effects of the combination of lamivudine and adefovir
      dipivoxil compared to adefovir alone in suppressing hepatitis B and prevention of lamivudine
      resistant mutants that arise during long-term therapy with lamivudine alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintained Combined Response (Virological, Biochemical and Histological Response).</measure>
    <time_frame>196 weeks from randomization</time_frame>
    <description>A maintained combined response was defined as a combination of a virological, biochemical and histological responses at weeks 48 and 192. A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (&lt;500 copies/mL). A biochemical response was defined as a decrease in serum ALT levels into the normal range (&lt;41 U/L). A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBeAg Loss at Week 196</measure>
    <time_frame>Week 196 from randomization</time_frame>
    <description>Loss of hepatitis B surface antigen (HBsAg) at week 196</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Response</measure>
    <time_frame>Week 196 from randomization</time_frame>
    <description>A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (&lt;500 copies/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Response</measure>
    <time_frame>week 196 from randomization</time_frame>
    <description>A biochemical response was defined as a decrease in serum ALT levels into the normal range (&lt;41 U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Response</measure>
    <time_frame>week 196 from randomization</time_frame>
    <description>A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>HBV (Hepatitis B Virus)</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>Lamivudine and adefovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine and adefovir</intervention_name>
    <description>Lamivudine (100 mg/day) and adefovir (10 mg/day)</description>
    <arm_group_label>Lamivudine and adefovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir alone</intervention_name>
    <description>Adefovir (10 mg/day)</description>
    <arm_group_label>Adefovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age greater than 18 years and above, male or female

        Known serum HBsAg positivity for at least 6 months

        Detectable HBV-DNA in serum above 1 million copies per ml, as detected by quantitative PCR
        (Roche Cobas Assay)

        Serum ALT (alanine aminotransferase) or AST (aspartate aminotransferase)levels above the
        upper limit of normal based on two determinations taken at least one month apart during the
        6 months before entry

        Liver biopsy within 2 years consistent with chronic hepatitis and with a histology activity
        index score (HAI) of 6 or more (out of a total possible score of 22) and an &quot;Ishak&quot;
        fibrosis score of at least 1 (out of a total possible score of 6). For patients with
        lamivudine resistance the liver biopsy may be performed either on or off lamivudine.

        Written informed consent.

        EXCLUSION CRITERIA:

        Previous or current treatment with adefovir or tenofovir.

        Co-infection with HDV (Hepatitis D Virus) as defined by the presence of both anti-HDV in
        serum and HDV antigen in liver

        Co-infection with HCV (Hepatitis C Virus) as defined by the presence of both anti-HCV and
        HCV RNA in serum.

        Co-infection with HIV (Human immunodeficiency virus) as defined by the presence of anti-HIV
        in serum.

        Decompensated liver disease as defined by serum bilirubin greater than 2.5 mg%, prothrombin
        time of greater than 2 seconds prolonged, a serum albumin of less than 3.0 gm%, or a
        history of ascites, variceal bleeding, or hepatic encephalopathy.

        Presence of other causes of liver disease (i.e., hemochromatosis, Wilson's disease,
        alcoholic liver disease, non-alcoholic steatohepatitis, alpha-1 antitrypsin deficiency)

        A history of organ transplantation or in the absence of organ transplantation, any
        immunosuppressive therapy requiring the use of more than 5 mg of prednisone (or its
        equivalent) daily.

        Significant systemic illnesses other than liver diseases including congestive heart
        failure, renal failure, chronic pancreatitis, diabetes mellitus with poor control that in
        the opinion of the investigators might interfere with therapy.

        Pregnancy or inability to practice contraception in patients capable of bearing or
        fathering children

        Pre-existing bone marrow suppression: White Blood Cells (WBC) less than 2,000 cells/mm(3),
        hematocrit less than 30%, or platelets less than 50,000 cells/mm(3).

        History of clinically apparent pancreatitis or evidence of subclinical pancreatitis as
        shown by serum amylase values twice the upper limits of the normal range and abnormalities
        of the pancreas on CT or other imaging studies of the abdomen

        Prior interferon treatment within 6 months of entry

        Sensory or motor neuropathy apparent from medical history and physical examination

        Creatinine clearance less than 50 ml/min or serum creatinine greater than 1.5 mg/dl;
        creatinine clearance will be determined on a 24 hour urine specimen. Accuracy of collection
        will be ensured by documenting appropriate total creatinine excretion in the 24 hour urine
        specimen (15 mg/kg) and correcting for the patient's age and gender.

        Concurrent use of nephrotoxic agents (e.g., aminoglycosides, amphotericin B, vancomycin,
        foscarnet, cis-platinum, pentamidine, nonsteroidal anti-inflammatory agents) or competitors
        of renal tubular excretion (e.g., probenecid) within 2 months prior to study screening or
        the expectation that the subject will receive these during the course of the study

        History of hypersensitivity to nucleoside/nucleotide analogues

        Active ethanol/drug abuse/psychiatric problems that, in the investigator's opinion, might
        interfere with participation in the study

        History of seizure disorder

        History of renal tubular acidosis

        History of malignancy or treatment for a malignancy within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghany Mark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2001-DK-0246.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996 May 30;334(22):1422-7.</citation>
    <PMID>8618580</PMID>
  </reference>
  <reference>
    <citation>Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med. 2000 May 2;132(9):723-31. Review.</citation>
    <PMID>10787366</PMID>
  </reference>
  <reference>
    <citation>Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997 Jan 30;336(5):347-56. Review.</citation>
    <PMID>9011789</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2001</study_first_submitted>
  <study_first_submitted_qc>September 1, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2001</study_first_posted>
  <results_first_submitted>July 7, 2011</results_first_submitted>
  <results_first_submitted_qc>February 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</investigator_affiliation>
    <investigator_full_name>Marc Ghany, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Adefovir Dipivoxil</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Nucleoside/Nucleotide Analogue</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Hepatitis B Mutants</keyword>
  <keyword>Liver Biopsy</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>HBV</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty-one patients were enrolled, twenty-two were randomized to receive the combination lamivudine and adefovir and nineteen to receive adefovir alone.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lamivudine and Adefovir</title>
          <description>Patients to receive combination lamivudine and adefovir, with lamivudine of 100 mg daily and adefovir of 10 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Adefovir</title>
          <description>Patients to receive adefovir alone (10 mg daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lamivudine and Adefovir</title>
          <description>Patients to receive combination lamivudine and adefovir</description>
        </group>
        <group group_id="B2">
          <title>Adefovir</title>
          <description>Patients to receive adefovir alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="14"/>
                    <measurement group_id="B2" value="45" spread="13"/>
                    <measurement group_id="B3" value="45" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Naive</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBeAg positive</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT</title>
          <description>Alanine transaminase</description>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183" spread="250"/>
                    <measurement group_id="B2" value="87" spread="56"/>
                    <measurement group_id="B3" value="139" spread="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV DNA Log 10 copies per ml</title>
          <description>Hepatitis B virus DNA logarithm 10 copies per ml</description>
          <units>log10(copies/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="1.3"/>
                    <measurement group_id="B2" value="7.8" spread="1.6"/>
                    <measurement group_id="B3" value="8.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAI</title>
          <description>HAI Fibrosis score for liver histology, which has a range 0–18 and higher values represent a worse outcome</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="2.7"/>
                    <measurement group_id="B2" value="7.9" spread="2.4"/>
                    <measurement group_id="B3" value="8.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ishak</title>
          <description>Ishak Fibrosis Score, (range 0–6, where 0 = no fibrosis and 6 = cirrhosis)</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.7"/>
                    <measurement group_id="B2" value="2.4" spread="1.5"/>
                    <measurement group_id="B3" value="2.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cirrhosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maintained Combined Response (Virological, Biochemical and Histological Response).</title>
        <description>A maintained combined response was defined as a combination of a virological, biochemical and histological responses at weeks 48 and 192. A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (&lt;500 copies/mL). A biochemical response was defined as a decrease in serum ALT levels into the normal range (&lt;41 U/L). A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score.</description>
        <time_frame>196 weeks from randomization</time_frame>
        <population>The analysis was intention to treat. Patients with missing values at week 196 were treated as random missing. No imputation was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamivudine and Adefovir</title>
            <description>Patients to receive combination lamivudine and adefovir</description>
          </group>
          <group group_id="O2">
            <title>Adefovir</title>
            <description>Patients to receive adefovir alone</description>
          </group>
        </group_list>
        <measure>
          <title>Maintained Combined Response (Virological, Biochemical and Histological Response).</title>
          <description>A maintained combined response was defined as a combination of a virological, biochemical and histological responses at weeks 48 and 192. A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (&lt;500 copies/mL). A biochemical response was defined as a decrease in serum ALT levels into the normal range (&lt;41 U/L). A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score.</description>
          <population>The analysis was intention to treat. Patients with missing values at week 196 were treated as random missing. No imputation was applied.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in the treatment effect between the two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0294</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBeAg Loss at Week 196</title>
        <description>Loss of hepatitis B surface antigen (HBsAg) at week 196</description>
        <time_frame>Week 196 from randomization</time_frame>
        <population>Analysis was intention to treat. Patients with missing values at timeframe of interest was taken as random missing. No imputation was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamivudine and Adefovir</title>
            <description>Patients to receive combination lamivudine and adefovir</description>
          </group>
          <group group_id="O2">
            <title>Adefovir</title>
            <description>Patients to receive adefovir alone</description>
          </group>
        </group_list>
        <measure>
          <title>HBeAg Loss at Week 196</title>
          <description>Loss of hepatitis B surface antigen (HBsAg) at week 196</description>
          <population>Analysis was intention to treat. Patients with missing values at timeframe of interest was taken as random missing. No imputation was applied.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in treatment effect at week 196</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0325</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Response</title>
        <description>A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (&lt;500 copies/mL).</description>
        <time_frame>Week 196 from randomization</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Lamivudine and Adefovir</title>
            <description>Patients to receive combination lamivudine and adefovir</description>
          </group>
          <group group_id="O2">
            <title>Adefovir</title>
            <description>Patients to receive adefovir alone</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Response</title>
          <description>A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (&lt;500 copies/mL).</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in treatment effect at week 196</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biological Response</title>
        <description>A biochemical response was defined as a decrease in serum ALT levels into the normal range (&lt;41 U/L).</description>
        <time_frame>week 196 from randomization</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Lamivudine and Adefovir</title>
            <description>Patients to receive combination lamivudine and adefovir</description>
          </group>
          <group group_id="O2">
            <title>Adefovir</title>
            <description>Patients to receive adefovir alone</description>
          </group>
        </group_list>
        <measure>
          <title>Biological Response</title>
          <description>A biochemical response was defined as a decrease in serum ALT levels into the normal range (&lt;41 U/L).</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in treatment effect at week 196</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0157</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Response</title>
        <description>A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score.</description>
        <time_frame>week 196 from randomization</time_frame>
        <population>Analysis was intention to treat. Patients with missing values at timeframe of interest was taken as random missing. No imputation was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamivudine and Adefovir</title>
            <description>Patients to receive combination lamivudine and adefovir</description>
          </group>
          <group group_id="O2">
            <title>Adefovir</title>
            <description>Patients to receive adefovir alone</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Response</title>
          <description>A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score.</description>
          <population>Analysis was intention to treat. Patients with missing values at timeframe of interest was taken as random missing. No imputation was applied.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference in treatment effect at week 196</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0913</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lamivudine and Adefovir</title>
          <description>Patients to receive combination lamivudine and adefovir</description>
        </group>
        <group group_id="E2">
          <title>Adefovir</title>
          <description>Patients to receive adefovir alone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc G. Ghany, M.D</name_or_title>
      <organization>National Institute of Diabetes and Digestive and Kidney Diseases, NIH</organization>
      <phone>3014961721</phone>
      <email>marcg@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

